Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of lugdunin in China, also supports custom service. Welcome to wholesale bulk high quality lugdunin from our factory. Contact us for more details.
| Description | Lugdunin (CAS: 1989698-37-4) is a novel cyclic peptide antibiotic produced by the human nasal/skin commensal Staphylococcus lugdunensis via non-ribosomal peptide synthetase. Molecular formula C40H62N8O6S, MW 783.05 Da. Lugdunin contains a characteristic thiazolidine ring and multiple D-amino acids; acting as a cationic ionophore it drives cation influx, rapidly depolarizing the cytoplasmic membrane and acidifying the cytoplasm to deplete ATP, potently cidal against Gram-positive pathogens including MRSA, VRE, and Listeria monocytogenes. Carriers of S. lugdunensis show markedly reduced S. aureus skin/nasal colonization. Lugdunin also induces LL-37 and CXCL8/MIP-2 in human keratinocytes and mouse skin, amplifying host- and microbiota-derived innate immunity. Lugdunin is a landmark tool for skin commensal colonization resistance and resistance-irreversible cyclic peptide antibiotics. |
| Structure type | Non-ribosomal cyclic peptide (thiazolidine ring + multiple D-aa, S. lugdunensis) |
| Solubility | Readily soluble in DMSO, methanol |
| Storage | Powder -20C, dry, protected from light |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Salt Form | Length (aa) |
| Lugdunin | Lugdunin; S. lugdunensis cyclic peptide antibiotic; thiazolidine cyclopeptide; NRPS product; CAS 1989698-37-4 | heterocyclic peptide antibiotic, non-ribosomal peptide, NRPS, thiazolidine ring, anti-MRSA, membrane depolarization, proton ionophore, microbiome-derived antimicrobial, head-to-tail cyclic peptide, D-amino acid peptide | 7-residue head-to-tail cyclic non-ribosomal peptide (NRP), formula C40H62N8O6S; residues: D-Leu, L-Val, D-Val, Cys-derived thiazolidine ring, D-Val, L-Val, L-Trp, in an alternating D/L chirality; the unique thiazolidine five-membered ring forms by condensation of the Cys side chain with an N-terminal aldehyde generated by the NROS terminal reductase domain, accompanied by a reduced amide bond (psi[CH-NH], carbonyl reduced to methyleneamine) - this distinguishes lugdunin from ordinary thiazole-containing peptides (e.g., microcins/nisin) which have oxidized aromatic thiazoles; no free N-terminus or C-terminus, no Arg/Lys/His/Asp/Glu charged side chains; Trp indole is the only aromatic heterocycle; overall highly hydrophobic (4 Val + 1 Leu + 1 Trp), extremely poor water solubility; net neutral charge | C40H62N8O6S | 782.45 | 783.05 | Free base; neutral molecule, no salt form | 7 |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage | Short-term Storage | Solution Stability | Solid Powder Stability |
| PEP-LUGDU-01 | White powder | -20°C, desiccated, sealed, protected from light; contains Trp so must be strictly light-protected (foil wrap); alternating D/L cyclic backbone is highly resistant to proteolysis, structurally stable; highly hydrophobic, low hygroscopicity | 2-8°C, desiccated, protected from light, for weeks; DMSO stock solutions stable ~2 weeks at 4°C | Extremely poor water solubility (strongly hydrophobic cyclic peptide); must be dissolved in DMSO or DMF as stock (>=5 mg/mL, sonication recommended); aggregates/precipitates in aqueous media, dilute freshly in culture medium or buffer before use; Trp is light- and oxidation-sensitive in solution, aliquot stocks and store protected from light at -80°C (~6 months), avoid repeated freeze-thaw | solid is highly stable; cyclic structure + D-amino acids + thiazolidine ring confer high chemical and proteolytic stability; conventional dry sealed light-protected storage suffices long-term |
Functional Description
| Product Code | Frontend Short Summary | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Pathways |
| PEP-LUGDU-01 | The first microbiome-derived cyclic peptide antibiotic from human nasal/skin commensal Staphylococcus lugdunensis, featuring a unique thiazolidine ring; acts as a cation ionophore that dissipates bacterial membrane potential, potently anti-MRSA and anti-VRE; a paradigm for skin microbiota protecting the host from pathogen colonization. | Lugdunin is a novel non-ribosomal cyclic peptide antibiotic produced by the human nasal commensal Staphylococcus lugdunensis, reported by Zipperer et al. in Nature (2016), and the first antimicrobial peptide discovered from the human microbiome. Its biosynthetic gene cluster (lugA-lugF) resides on a ~30 kbp NRPS operon. The structure was solved by NMR, HRMS, and Marfey's analysis: lugdunin is a 7-residue head-to-tail cyclic peptide containing D-Leu, L-Val, D-Val, D-Val, L-Val, L-Trp, and a Cys-derived thiazolidine ring, with an alternating D/L backbone. Its most distinctive feature is the thiazolidine ring - unlike the aromatic thiazoles formed by oxidative dehydration of Cys-carbonyl in ordinary ribosomal peptides (e.g., microcins, nisin), lugdunin's thiazolidine is formed when the NRPS terminal reductase domain reduces the N-terminus to an aldehyde that spontaneously condenses with the Cys side-chain thiol and amine, accompanied by a reduced secondary amine bond (psi[CH-NH]), defining a novel cyclic peptide scaffold. Functionally, lugdunin shows micromolar activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and Listeria monocytogenes. Mechanistic studies revealed that lugdunin does not inhibit a specific enzymatic target (e.g., fatty acid synthase) but acts as a cation ionophore mediating proton/cation translocation across the membrane, rapidly dissipating the bacterial cytoplasmic membrane potential, acidifying the cytoplasm, and causing energy depletion and bacterial death. It also synergizes with host- and microbiota-derived factors to upregulate LL-37 and CXCL8/MIP-2 in human keratinocytes and mouse skin. The discovery is landmark: it demonstrates that human commensal microbiota can produce chemicals that directly inhibit pathogens, providing molecular evidence for 'microbiota-host co-defense' and opening avenues for anti-MRSA drug discovery and skin microbiota therapeutics (probiotics/live biotherapeutics). Its D/L alternating backbone and thiazolidine ring are highly resistant to proteolysis, giving lugdunain prolonged residence on the skin surface, suitable for topical anti-infective applications. | microbiome-derived antibiotics, anti-MRSA drug discovery, non-ribosomal peptides (NRPS), thiazolidine cyclopeptides, membrane ionophore mechanism, skin/nasal microbiota defense, live biotherapeutics | bacterial cytoplasmic membrane potential (cation/proton ionophore), MRSA, VRE, Listeria monocytogenes |
Hot Tags: lugdunin, China lugdunin manufacturers, suppliers, factory, 143459-88-5, 3032621-32-9, 79404-91-4, CAS 143459 88 5, CAS 79404 91 4, Elf18
